Ratings by Mizuho (Uy Ear)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/3/2026 | uniQure BV | QURE | Downgrade | Neutral (Outperform) |
15.63 (14.27) |
-8.7% | Details | |
| 3/2/2026 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Outperform (N/A) |
|
Details | ||
| 2/23/2026 | Acadia Pharmaceuticals | ACAD | Upgrade | Outperform (Neutral) |
24.33 (22.16) |
-8.92% | Details | |
| 1/14/2026 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 12/11/2025 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 12/9/2025 | uniQure BV | QURE | Maintain | Outperform (N/A) |
|
Details | ||
| 11/28/2025 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/20/2025 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/19/2025 | Relmada Therapeutics Inc | RLMD | Upgrade | Outperform (Neutral) |
3.97 (4.45) |
12.09% | Details | |
| 11/7/2025 | MBX Biosciences Inc | MBX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/5/2025 | Sarepta Therapeutics | SRPT | Upgrade | Outperform (Neutral) |
24.45 (16.71) |
-31.66% | Details | |
| 10/29/2025 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Outperform (N/A) |
|
Details | ||
| 10/14/2025 | Tectonic Therapeutics Inc. | TECX | Maintain | Outperform (Outperform) |
|
Details | ||
| 10/13/2025 | IN8bio Inc. | INAB | Maintain | Outperform (N/A) |
|
Details | ||
| 10/7/2025 | Sarepta Therapeutics | SRPT | Maintain | Neutral (Neutral) |
|
Details | ||
| 10/7/2025 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Outperform (N/A) |
|
Details | ||
| 9/25/2025 | uniQure BV | QURE | Upgrade | Outperform (Outperform) |
47.50 (15.63) |
-67.09% | Details | |
| 9/25/2025 | uniQure BV | QURE | Maintain | Outperform (N/A) |
|
Details | ||
| 9/24/2025 | MBX Biosciences Inc | MBX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/15/2025 | uniQure BV | QURE | Maintain | Outperform (N/A) |
|
Details | ||
| 8/24/2025 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 8/14/2025 | uniQure BV | QURE | Upgrade | Outperform (Neutral) |
14.60 (47.50) |
225.34% | Details | |
| 8/7/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 8/5/2025 | MBX Biosciences Inc | MBX | New Coverage | Outperform (N/A) |
12.54 (30.55) |
143.62% | Details | |
| 7/30/2025 | Sarepta Therapeutics | SRPT | Maintain | (N/A) |
|
Details | ||
| 7/21/2025 | Sarepta Therapeutics | SRPT | Downgrade | Neutral (Outperform) |
21.97 (24.45) |
11.29% | Details | |
| 7/17/2025 | Sarepta Therapeutics | SRPT | Maintain | Outperform (Outperform) |
|
Details | ||
| 7/2/2025 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 6/18/2025 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 5/19/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 5/9/2025 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 4/21/2025 | Tectonic Therapeutics Inc. | TECX | New Coverage | Outperform (N/A) |
17.02 (35.87) |
110.75% | Details | |
| 3/26/2025 | Relmada Therapeutics Inc | RLMD | Maintain | Neutral (N/A) |
|
Details | ||
| 3/18/2025 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 2/27/2025 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 2/26/2025 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Outperform (N/A) |
|
Details | ||
| 2/6/2025 | Relmada Therapeutics Inc | RLMD | Maintain | Neutral (N/A) |
|
Details | ||
| 1/27/2025 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 1/6/2025 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Outperform (N/A) |
|
Details | ||
| 12/19/2024 | uniQure BV | QURE | Maintain | Neutral (N/A) |
|
Details | ||
| 12/5/2024 | Relmada Therapeutics Inc | RLMD | Downgrade | Neutral (Outperform) |
2.77 (3.97) |
43.32% | Details | |
| 11/26/2024 | Sarepta Therapeutics | SRPT | Maintain | Outperform (Outperform) |
|
Details | ||
| 11/14/2024 | IN8bio Inc. | INAB | Maintain | Outperform (N/A) |
|
Details | ||
| 10/10/2024 | Sarepta Therapeutics | SRPT | Maintain | Outperform (Outperform) |
|
Details | ||
| 10/3/2024 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/25/2024 | Cartesian Therapeutics | RNAC | Maintain | Outperform (N/A) |
|
Details | ||
| 8/16/2024 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Outperform (N/A) |
|
Details | ||
| 8/7/2024 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 8/2/2024 | uniQure BV | QURE | Maintain | Neutral (N/A) |
|
Details | ||
| 7/23/2024 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Outperform (N/A) |
|
Details | ||
| 7/9/2024 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Outperform (Outperform) |
|
Details | ||
| 7/3/2024 | Cartesian Therapeutics | RNAC | Maintain | Outperform (Outperform) |
|
Details | ||
| 6/24/2024 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 5/24/2024 | Cartesian Therapeutics | RNAC | New Coverage | Outperform (N/A) |
25.46 (6.85) |
-73.1% | Details | |
| 5/17/2024 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 5/15/2024 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Outperform (N/A) |
|
Details | ||
| 5/9/2024 | Acadia Pharmaceuticals | ACAD | Maintain | Neutral (N/A) |
|
Details | ||
| 5/8/2024 | uniQure BV | QURE | Maintain | Neutral (N/A) |
|
Details | ||
| 3/12/2024 | Acadia Pharmaceuticals | ACAD | Downgrade | Neutral (Outperform) |
23.44 (24.33) |
3.8% | Details | |
| 3/12/2024 | Acadia Pharmaceuticals | ACAD | Downgrade | Neutral () |
23.44 (23.44) |
0% | Details | |
| 3/4/2024 | uniQure BV | QURE | Maintain | Neutral (N/A) |
|
Details | ||
| 2/28/2024 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2024 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 2/23/2024 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Outperform (N/A) |
|
Details | ||
| 2/14/2024 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 2/9/2024 | IN8bio Inc. | INAB | New Coverage | Outperform (N/A) |
1.22 (1.72) |
40.98% | Details | |
| 1/10/2024 | Arcutis Biotherapeutics Inc. | ARQT | Upgrade | Outperform (Neutral) |
4.05 (24.00) |
492.59% | Details | |
| 1/3/2024 | Arcutis Biotherapeutics Inc. | ARQT | Upgrade | (Neutral) |
3.23 (24.00) |
643.03% | Details | |
| 1/3/2024 | Arcutis Biotherapeutics Inc. | ARQT | Upgrade | Outperform (Neutral) |
3.23 (24.00) |
643.03% | Details | |
| 12/28/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Outperform (N/A) |
|
Details | ||
| 12/20/2023 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 12/18/2023 | uniQure BV | QURE | Downgrade | Neutral (Outperform) |
8.27 (14.60) |
76.54% | Details | |
| 12/18/2023 | Avrobio Inc. | AVRO | Maintain | Outperform (N/A) |
|
Details | ||
| 12/18/2023 | Avrobio Inc. | AVRO | Downgrade | Neutral (Outperform) |
1.36 (1.40) |
2.94% | Details | |
| 11/6/2023 | Acadia Pharmaceuticals | ACAD | Upgrade | Outperform (Neutral) |
24.07 (22.16) |
-7.94% | Details | |
| 11/6/2023 | Acadia Pharmaceuticals | ACAD | Upgrade | (Neutral) |
22.99 (22.16) |
-3.61% | Details | |
| 10/26/2023 | Arcutis Biotherapeutics Inc. | ARQT | Downgrade | Neutral (Outperform) |
2.39 (24.00) |
904.18% | Details | |
| 9/25/2023 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 8/18/2023 | Selecta Biosciences | SELB | Maintain | Outperform (N/A) |
|
Details | ||
| 5/10/2023 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Outperform (N/A) |
|
Details | ||
| 4/13/2023 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 3/24/2023 | Avrobio Inc. | AVRO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/22/2023 | Selecta Biosciences | SELB | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2023 | Selecta Biosciences | SELB | Maintain | Outperform (N/A) |
|
Details | ||
| 3/1/2023 | Ocugen, Inc. | OCGN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/8/2023 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Outperform (N/A) |
|
Details | ||
| 9/28/2022 | Ocugen, Inc. | OCGN | Maintain | Outperform (Outperform) |
|
Details | ||
| 8/26/2022 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Outperform (N/A) |
|
Details | ||
| 8/23/2022 | Ocugen, Inc. | OCGN | New Coverage | Outperform (N/A) |
2.45 (1.61) |
-34.29% | Details | |
| 6/28/2022 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Outperform (Outperform) |
|
Details | ||
| 6/24/2022 | Sarepta Therapeutics | SRPT | Maintain | Outperform (Outperform) |
|
Details | ||
| 5/25/2022 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Outperform (Outperform) |
|
Details | ||
| 5/6/2022 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Outperform (Outperform) |
|
Details | ||
| 5/3/2022 | Arcutis Biotherapeutics | AQRT | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/7/2022 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/28/2022 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/23/2022 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/10/2022 | Selecta Biosciences | SELB | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/9/2022 | Avrobio Inc. | AVRO | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/1/2022 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Outperform (Outperform) |
|
Details | ||
| 1/20/2022 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Outperform (Outperform) |
|
Details | ||
| 1/18/2022 | Arcutis Biotherapeutics Inc. | ARQT | Maintain | Outperform (Outperform) |
|
Details | ||
| 1/5/2022 | Avrobio Inc. | AVRO | Maintain | Outperform (N/A) |
|
Details | ||
| 12/2/2021 | uniQure BV | QURE | New Coverage | Outperform (N/A) |
27.85 (14.27) |
-48.76% | Details | |
| 12/2/2021 | Selecta Biosciences | SELB | New Coverage | Outperform (N/A) |
3.00 (0.88) |
-70.67% | Details | |
| 12/2/2021 | Sarepta Therapeutics | SRPT | New Coverage | Outperform (N/A) |
80.81 (21.97) |
-72.81% | Details | |
| 12/2/2021 | Avrobio Inc. | AVRO | New Coverage | Outperform (N/A) |
3.84 (1.40) |
-63.54% | Details | |
| 6/30/2021 | Arcutis Biotherapeutics Inc. | ARQT | New Coverage | Outperform (N/A) |
27.05 (24.00) |
-11.28% | Details |
